{
    "nctId": "NCT02124148",
    "briefTitle": "A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer",
    "officialTitle": "A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors",
    "overallStatus": "COMPLETED",
    "conditions": "Neoplasm Metastasis, Colorectal Neoplasms, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 167,
    "primaryOutcomeMeasure": "Part A: Maximum Tolerated Dose and Schedule of Prexasertib in Combination with Cisplatin",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Must be appropriate candidate for experimental therapy, as determined by investigator, after available standard therapies have failed\n* Have adequate organ function\n* Prior Therapies: Systemic treatments: must have discontinued previous systemic treatments for cancer and recovered from the acute effects of therapy. Participants must have discontinued mitomycin-C or nitrosourea therapy at least 42 days and have discontinued any cytotoxic therapies at least 28 days prior to study enrollment. Radiation therapy and surgery: must be completed at least 4 weeks before study enrollment\n* All parts except Part B, Part E2, and Part E3 dose expansion: Must have diagnosis of cancer that is advanced or metastatic\n* Part B dose expansion: Must have confirmed Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type colorectal cancer that is metastatic or recurrent and has failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant of irinotecan or oxaliplatin\n* Part E2 dose expansion: must have cancer that is advanced or metastatic and have prior documentation of a mutation of PIK3CA\n* Part E3 dose expansion: must have advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer\n* Must be available during the duration of the study and willing to follow the study procedures\n* Parts A and B: If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for six months following the last dose of study drug\n* Parts C, D and E: If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug\n* If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 14 days of the first dose of study drug and must not be breast feeding\n* Part E: Are able to swallow capsules or tablets\n\nExclusion Criteria:\n\n* Have received more than 2 previous lines of cytotoxic chemotherapy (if receiving cisplatin, 5-FU or pemetrexed)\n* Must not have taken an unapproved drug as treatment for any indication within the last 28 days prior to starting study treatment\n* Must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C\n* Must not have a serious heart condition, such as congestive heart failure, unstable angina pectoris, or heart attack within the last three months\n* Must not have a family history of long QTc syndrome\n* Must not have a serotonin-secreting carcinoid tumor or a prior history of drug-induced serotonin syndrome\n* Must not have acute leukemia\n* Part E: Have insulin-dependent (type I) diabetes or a history of gestational diabetes\n* Part E: Prior treatment with a PI3K/mTOR inhibitor",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}